The signal transducers and activators of transcription (STATs) were originally identified 10 years ago, as playing a necessary role in signaling downstream of the interferon receptors Schindler and Song, 2003) . A plethora of work over the next 5 years expanded on this knowledge and demonstrated that these proteins were activated in response to ligand binding to many cytokine receptors, including growth hormone (GH), prolactin (Prl), and erythropoietin (Epo), as well as several growth factor receptors (Leaman et al., 1996; Ihle, 2003) . Seven STAT proteins have been identified, and of these, STATs 2, 4 and 6 are activated specifically by a small subset of cytokines (IFNa, 12, 13, respectively) . In contrast, STATs 1, 3, 5a, and 5b can be activated not only by a large array of cytokines, but also by growth factors (EGF, PDGF, insulin, IGF-1, and others), as well as some G-protein coupled receptor agonists (Brivanlou and Darnell, 2002; Levy and Darnell, 2002; O'Shea et al., 2002) . The pattern of STAT activation is often cell type and ligand specific. Because of the wide array of ligands and growth factors that can activate them, STATs are involved in a broad spectrum of cellular events including differentiation, proliferation, and apoptosis (Bromberg and Darnell, 2000) . Thus, it is not surprising that more recent studies have led to an increasing awareness of the potential role of STATs (1, 3, 5a, 5b) in oncogenic pathways (Calo et al., 2003) .
All seven STAT proteins share a highly homologous domain structure as shown in Figure 1 . These include an N-terminal domain involved in protein-protein interactions, a DNA-binding domain that binds to consensus sites upstream of regulated genes, and an SH-2 domain that interacts with tyrosine phosphorylated residues on receptors and/or kinases (Kisseleva et al., 2002) . In all cases, activation of the STAT proteins involves a tyrosine phosphorylation cascade. Initially, this cascade was shown to involve recruitment by the nontyrosine kinase containing cytokine receptors of the cytosolic tyrosine kinases of the JAK family (tyk2, Jak1,2,3). Recruitment of the JAKs to the ligand-induced receptor dimer leads to JAK transphosphorylation and activation followed by receptor and STAT tyrosine phosphorylation. Recruitment of a STAT protein to the receptor kinase complex occurs through the interaction of its SH2 domain with a phosphorylated tyrosine residue at the receptor or kinase complex. STATs are then phosphorylated at a single tyrosine residue in the Cterminal domain. Activation occurs when the STAT proteins form hetero-or homodimers through tyrosine phosphorylation-SH2 domain interaction, after which the STAT dimer translocates to the nucleus. In the nucleus, STAT dimers interact, through their DNAbinding domain with consensus DNA elements upstream of regulated genes. See model in Figure 1 . Many genes known to contain STAT consensus elements upstream of their promoters have been identified and not surprisingly, the proteins for which these genes encode play a role in cellular proliferation, differentiation, and apoptosis. However, by no means have all STAT-regulated genes been identified and there is still much to be learned about STAT-specific and cell typespecific signaling.
Activation of STATs by Src family kinases

STATs as a mediator of SFK-induced transformation
The initial evidence that Src family kinases (SFKs) could be involved in STAT activation came from models of vSrc transformation. In 1995, Yu et al. showed that the DNA-binding activity of STAT3 was enhanced in cells transformed by the v-Src oncoprotein (Yu et al., 1995) . This model of v-Src transformation led to further studies that resulted in a more detailed analysis of the molecular mechanism of v-Src activation of STAT3. In a number of cell models, it was shown not only that vSrc could activate STAT3 in a JAK-independent manner, but that there was an association between STAT3 and v-Src. Furthermore, v-Src was shown to activate not only the tyrosine phosphorylation of STAT3 but also DNA binding, and transcriptional activation (Cao et al., 1996) . Although there are numerous studies, which demonstrate that the kinase activity of JAK is not required for STAT3 activation, the JAK protein may still play a role in recruiting STAT3 to the Src complex (Zhang et al., 2000) . Most importantly, a number of studies demonstrated not only that the full oncogenic activity of v-Src depended on STAT3, but that STAT3 activation was required for vSrc transformation (Bromberg et al., 1998; Turkson et al., 1998; Odajima et al., 2000) . Similarly, Kazansky et al. demonstrated that STAT5b could potentiate v-Srcmediated transformation of NIH-3T3 cells (Kazansky and Rosen, 2001) . Together, these types of studies provided evidence of an alternative pathway of STAT activation that was independent of the JAK kinase activity and dependent on another family of intracellular tyrosine kinases, the SFKs. Furthermore, this activation pathway leads to cellular transformation.
STAT activation by other SFKs
Although Src activation of STATs is the most wellcharacterized model, there is evidence that STATs can be activated by other members of the Src Family Kinases (SFKs). For example, lck, which is expressed predominantly in hematopoietic cells, has been shown to activate the JAK/STAT pathway in T lymphocytes and to induce STAT3 tyrosine phosphorylation and DNA binding (Lund et al., 1997 (Lund et al., , 1999 Yu et al., 1997) . Lyn, another hematopoietic SFK, plays an essential role in activation of the STAT5 pathway by the cytokine, erythropoietin (Chin et al., 1998) . A series of in vitro studies in insect cells, showed that src, hck, lyn, fyn, and Figure 1 Model of STAT signaling. Signal transducers and activators of transcription (STAT) are activated by cytokine and growth factor receptors. In the case of the nontyrosine containing cytokine receptors, the JAK kinases are recruited to the receptor complex and phosphorylate the receptor on tyrosine. This phosphorylation leads to recruitment of the STAT protein to the receptor/kinase complex through the SH2 domain of the STAT. The STAT is then tyrosine phosphorylated (Y) at a single residue in its C-terminus. STATs can also be serine phosphorylated (S) in their transactivation domain (TAD). In the case of growth factor receptors, the kinase activity of the receptor is able to directly phosphorylate the STAT protein. In either case, tyrosine phosphorylation of the STATs leads to STAT dimerization (through tyrosine (Y) and SH2 domain interaction (as shown in the nucleus). STATs then bind through their DNA-binding domain (DBD) to consensus elements (TTCTTGGAA, STAT5 consensus), resulting in gene transcription. Activation of STATs leads to proliferation, differentiation and/or apoptosis, depending on the cell context. GH, growth hormone; Prl, prolactin; IFNs, interferons; ILs, interleukins; CSFs, colony stimulating factors; EGF, epidermal growth factor; PDGF, platelet-derived growth factor; IGF, insulin-like growth factor fgr are all capable of tyrosine phosphorylating STAT3 (Schreiner et al., 2002) . These are just a few examples of SFKs, other than c-Src, that can activate STAT proteins. For a more comprehensive review of SFK activation of STATs see Silva et al. (2003) .
Role of c-Src in growth factor receptor signaling
In many cases, the activation of the STAT proteins by cSrc occurs downstream of growth factor receptor kinases. A well-described model of the cooperation of c-Src with growth factor receptors is that with the human epidermal growth factor receptor family (HER1/ EGFR, HER2/neu, HER3, HER4). A number of recent studies in both engineered as well as endogenous cell models, have shown that c-Src kinase activity is required for EGF, or other HER ligand, signaling to the STAT pathway. For example, NIH-3T3 cells that were engineered to overexpress various HER family members, exhibited growth factor-induced tyrosine phosphorylation and activation of four of the STAT proteins STATs 1,3,5a, and 5b (Olayioye et al., 1999) . However, expression of either a dominant-negative c-Src construct or treatment with a c-Src inhibitor, inhibited growth factor activation of the STATs. Thus, in this model system, c-Src kinase activity was required for HER family activation of the STATs. Similar experiments by Ren and Schaefer in HER2 overexpressing cells have demonstrated a role for c-Src and JAK2 in the activation of STAT3 (Ren and Schaefer, 2002) . These types of model systems provided evidence for a new mechanism of growth factor receptor activation of the STAT proteins.
Unique mechanism of c-Src activation of STAT5a/5b
Studies as discussed in the previous section elucidated a novel mechanism of STAT activation. It was discovered that activation of the STAT proteins by c-Src, either directly, or downstream of growth factor receptors, resulted in STAT proteins that were differentially activated when compared to cytokine activation of the STATs through the canonical JAK pathway. For example, c-Src (or growth factor) induced activation of STAT5 (5a or 5b) resulted in novel tyrosine phosphorylation sites in addition to the known sites (Tyr694 and Tyr699, respectively). Using a STAT5a tyrosine mutant, Olayioye et al. found that Y694F was tyrosine phosphorylated in response to EGF, but not by the cytokine prolactin, indicating a novel EGF-induced tyrosine phosphorylation that occurred at sites other than the well-described Tyr 694 (Olayioye et al., 1999) . Although the unique tyrosine phosphorylation sites were not identified, this work provided the first evidence of a unique STAT signaling pathway activated by c-Src and growth factor receptor cooperation. At about the same time, similar studies in a Cos cell transfection system demonstrated a differential activation of STAT5a and STAT5b by c-Src, again as compared to prolactin (Kazansky et al., 1999) . Immunofluorescent studies using STAT5a or STAT5b-specific antibodies demonstrated that when STAT5a was tyrosine phosphorylated in response to c-Src, it did not translocate to the nucleus, while STAT5b activated by c-Src did. However, despite its ability to translocate to the nucleus, c-Src-activated STAT5b was not able to activate transcription. These studies led to the conclusion that a STAT5 protein activated by c-Src was functionally very different than a STAT5 protein activated through a cytokine receptor. More recently, follow-up studies by the same group have shown that activation of STAT5b by c-Src results not only in unique c-Src-specific tyrosine phosphorylation sites, but also in a unique conformation of the STAT5b protein as seen by gel-shift analysis. Furthermore, STAT5b activated by c-Src displays a unique nuclear localization pattern as seen by immunofluorescence, when compared to the pattern of STAT5b activated by prolactin, again suggesting a novel function (Kabotyanski and Rosen, 2003) . Additional evidence of a unique model of EGFR/c-Src-induced activation was recently described in a rat hepatocyte model system (Guren et al., 2003) . Here, EGF-induced activation of STAT5b not only results in a unique tyrosine phosphorylation pattern of STAT5b, but its activation by EGF is dependent on c-Src kinase activity. Furthermore, the DNA-binding characteristics and activation pattern of the EGF-induced STAT5b is different than that seen by GH-induced activation of STAT5b in the same cells. We have also identified novel sites of STAT5b tyrosine phosphorylation in models of EGFR/c-Src co-overexpression in human breast cancer cell lines (Kloth et al., 2002 (Kloth et al., , 2003 . We identified these three novel sites as tyrosines 725, 740, and 743 found in the transactivation domain of STAT5b. These sites are phosphorylated in response to EGF, but not in response to the cytokines, growth hormone or prolactin. Furthermore, mutation of these three sites results in an increase in the basal transcriptional activity of STAT5b. This paradigm of STAT5b activation in the context of breast cancer will be discussed in more detail in the next section.
In summary, a unique mechanism of STAT activation in cells overexpressing c-Src and/or growth factor receptors that is different than that induced by cytokine activation of these STAT proteins has been revealed. This unique mechanism of activation includes novel tyrosine phosphorylation sites of STAT5a and STAT5b, as well as different patterns of nuclear localization and transcriptional activation. Because these events will affect the function of STAT proteins, and since c-Src (and growth factor receptors) are overexpressed and have increased activity in a number of cancers, the potentially important role of STAT proteins in these cancers is an active area of investigation.
Role of STAT proteins in carcinogenesis
Background
Given the key role of the STAT signaling cascade in cytokine signaling in hematopoietic cells, it is not surprising that these proteins have been well described as playing a role in many hematologic cancers. There is a large body of evidence supporting the role of constitutively active STAT3, STAT5a, and STAT5b in many leukemias, both acute and chronic forms. A recent review by Lin et al. provides an extensive review of the role of STATs in these cancers (Lin et al., 2000) . In addition to hematologic cancers, it is becoming increasingly well appreciated that the STAT proteins play a role in a number of solid tumors such as those of prostate, pancreas, breast, and head and neck. Again, in the large majority of these cases, the STATs involved in increased tumorigenicity are STAT3, STAT5b and STAT5a (Yu and Jove, 2004) . A large number of studies have been done in human tumor cell lines that are representative of each of these cancers that show an increase in STAT activation (Laird et al., 2003) . In these cellular models, it has been demonstrated that the molecular mechanism of STAT activation leads to escape from differentiation, and increased survival and proliferation. In some cases, the genes that are activated during these processes have been identified and they include, cyclin D1, c-myc, bcl xL , and p53. The c-Src tyrosine kinase is also overexpressed in a number of solid tumors including colon, breast, SCCHN, pancreatic, and lung among others (Biscardi et al., 1999b) . Models of breast cancer and squamous cell carcinoma of the head and neck (SCCHN) have provided mechanistic insight into the role of STAT proteins in c-Src overexpressing tumors. In both cases, c-Src is activated as a consequence of EGF receptor (or other HER family) overexpression and activation; and activation of the STATs is dependent on c-Src tyrosine kinase activity. Most importantly, activation of these STATs is required for tumor proliferation. Xi et al. have demonstrated that the c-Src kinase cooperates with the EGFR to activate STAT3 and STAT5 in models of SCCHN (Xi et al., 2003b) . Recently, this same group has demonstrated that the activation of STAT5b, not STAT5a, is required for tumor formation in both mouse xenograft models of SCCHN, as well as in primary human SCCHN tumors from patients (Xi et al., 2003a) . In the next section, we will describe a breast cancer model that will elucidate the intricate interaction between the c-Src tyrosine kinase, the growth factor receptor HER family, and the STAT3, STAT5a, STAT5b transcription factors in breast cancer.
Breast cancer model
Human epidermal growth factor receptor (HER) family members are overexpressed in 60% of breast cancers (Sainsbury et al., 1987; Toi et al., 1991; Harris et al., 1992) . HER2/neu is overexpressed in 60% of ductal carcinoma in situ (early stage), while overexpression of HER1, or the EGF receptor (EGFR), frequently is found in estrogen receptor-negative (ERÀ) breast cancers, characteristic of later stage, and more aggressive tumors. In addition, 70% of breast cancers overexpress the cellular tyrosine kinase, c-Src. Therefore in many later stage tumors, the EGFR and c-Src are cooverexpressed in the tumor cell. Biscardi and Tice used both a mouse fibroblast model engineered to overexpress either the EGFR, c-Src, or both, as well a panel of human breast cancer cell lines characterized with respect to EGFR and c-Src levels, in order to elucidate the molecular mechanism of c-Src/EGFR co-overexpression in breast tumorigenesis. For original references of the work described see (Biscardi et al., 1998; Biscardi et al., 1999a; Tice et al., 1999) . Their studies demonstrated that co-overexpression of c-Src and the EGFR led to an EGF-induced association of these two tyrosine kinases. Furthermore, cells that co-overexpressed the EGFR and c-Src were capable of increased transformation and tumor formation, as compared to cells that overexpressed either protein alone. In model cell lines, co-overexpression of the EGFR and c-Src tyrosine kinases led to a synergistic increase in mitogenesis, transformation, and tumorigenesis. Using a series of biochemical techniques, these investigators demonstrated that the association of these two kinases led to the c-Src-mediated phosphorylation of Tyr845 in the catalytic domain of the EGFR. Tyrosine 845 is not an EGFR autophosphorylation site rather, its phosphorylation requires the association of c-Src with the EGFR and the kinase activity of c-Src. The importance of this tyrosine phosphorylation is demonstrated by the observation that mutation of the EGFR at this tyrosine (Y845F) completely ablates EGF-induced DNA synthesis. Thus, these studies provided a unique role for the cSrc tyrosine kinase in EGFR signaling. By resulting in phosphorylation of a tyrosine residue of the EGFR that is not normally phosphorylated, co-overexpression of cSrc and EGFR in breast cancer leads to a unique signaling paradigm that does not normally exist in cells. Therefore, identification of downstream signaling molecules activated by this pathway could provide targets for therapeutic intervention in breast cancer, and potentially for other cancers that are characterized by c-Src/ EGFR overexpression. A number of studies from our laboratory, as well as others, have demonstrated the role of the STAT3, STAT5a and STAT5b proteins in downstream signaling emanating from c-Src/EGFR co-overexpression in models of breast cancer progression. The results and implications of these studies will be discussed below.
STAT3 Studies using the cellular models described above have provided evidence that STAT3 plays an important role in signaling in c-Src/EGFR co-overexpressing cells. Using the mouse fibroblasts that were engineered to overexpress either c-Src and/or the EGFR, Garcia et al. demonstrated that STAT3 was constitutively active and could bind to a STAT3 DNA consensus element in these cells (Garcia et al., 2001) . Furthermore, the use of kinase-specific inhibitors provided evidence that the constitutive activation of STAT3 in this model was dependent on the kinase activity of both c-Src and JAK. However, this constitutive STAT3 activation did not require the kinase activity of the EGFR. Rather, EGF was able to further induce STAT3 tyrosine phosphorylation and subsequent activation over and above the constitutive level. This additional activity was dependent on the EGFR kinase, and did not require the kinase activity of either c-Src or JAK. This paradigm of constitutive STAT3 activation was also confirmed in human breast cancer cell lines that overexpress c-Src and EGFR. In these same breast cancer cells, inhibition of STAT3 activity by expressing a dominant-negative STAT3 protein led to growth arrest and apoptosis of these cells. In order to determine the clinical relevance of STAT3 activation, primary breast tumor tissues were analyzed. Analysis by DNA binding to a STAT3-specific probe demonstrated an increased DNA-binding activity of STAT3 in tumor tissue as compared to the normal adjacent tissue. Together, these in vitro and in vivo studies provide evidence for the important role of the STAT3 transcription factor in breast cancer.
STAT5a and STAT5b
Our laboratory has investigated the role of the STAT5a and STAT5b transcription factors in the breast cancer models of c-Src and EGFR co-overexpression. For original references see (Kloth et al., 2002 (Kloth et al., , 2003 . In both mouse fibroblast models as well as human breast cancer cell lines, the activation of the STAT5 protein is dependent on EGFR overexpression. Initially, the activation of STAT5, as measured by tyrosine phosphorylation, DNA binding, or transcriptional activation, is dependent on stimulation by EGF; as the level of EGFR is increased, the STAT5 protein becomes constitutively active. Although overexpression of c-Src alone does not lead to the activation of STAT5, the kinase activity of c-Src is required for maximal tyrosine phosphorylation and transcriptional activation of STAT5 in response to EGF. That is, a c-Src inhibitor (PP2) as well as a kinase defective, dominant-negative form of c-Src (K-c-Src) greatly diminishes EGF-induced tyrosine phosphorylation and particularly transcriptional activation of STAT5. As discussed above, our studies also identified the EGF-induced phosphorylation of three tyrosine sites in the transcriptional activation domain (TAD) of STAT5b (tyrosines 725/ 740/743). These sites are phosphorylated in response to EGF but not the cytokines, growth hormone or prolactin; and these sites are phosphorylated in addition to Tyr699, the canonical activation site of STAT5b. Further mechanistic studies support the role of the c-Src tyrosine kinase in the phosphorylation of Tyr699 of STAT5b. We propose that the EGFR kinase is responsible for the phosphorylation of tyrosines 725/ 740/743. Furthermore, we found that mutation of these three tyrosines resulted in an increased basal activity of STAT5b. We hypothesize that these sites may be involved in the recruitment of cofactors to the TAD of STAT5b when it is in the transcriptional complex (see model, Figure 2 ). Phosphorylation of these sites provides a unique motif of STAT5b that exists only in EGFR overexpressing cells.
Our studies in breast cancer models have also demonstrated that STAT5b (and STAT5a) are downstream targets of the site of EGFR that is phosphorylated by c-Src kinase (Tyr845 Figure 2 STAT signaling in breast cancer models. In this model, the HER family receptors (such as EGFR or HER2/neu) as well as the c-Src tyrosine kinase are co-overexpressed. In this context, c-Src has multiple roles: (1) the phosphorylation of STAT3; (2) the phosphorylation of STAT5b; and (3) the phosphorylation of the EGFR at tyrosine 845 (Y845). The EGFR kinase also plays a role by (4) further phosphorylation of STAT3, and (5) phosphorylation of STAT5b at novel tyrosines (Y725/740/743). Together, these events lead to the activation of STAT5 and STAT3 proteins. This activation leads to STAT nuclear localization and binding to STAT-specific response elements (STATRE). Cofactors may also be part of the transcriptional complex leading to further modulation of STATregulated genes. Finally, the increases in genes that regulate cell proliferation and survival lead to tumorigenesis potential to directly phosphorylate STAT5b, this model provides a second mechanism by which c-Src is required for STAT5 activation. Mutation of Tyr845 of the EGFR (Y845F) inhibits EGF-induced tyrosine phosphorylation and transcriptional activation of STAT5b; supporting the important role of this site in STAT5 activation in breast cancer cells. Finally, similar to the studies described above with dominant-negative STAT3, we have shown that a dominant-negative STAT5 construct (either dnSTAT5b or dnSTAT5a) inhibits EGF-induced proliferation in these breast cancer models. Thus, as depicted in Figure 2 , c-Src and EGFR co-overexpression in breast cancer cells results in a unique signaling pathway to the STAT proteins. Activation of STAT3 is directly dependent on c-Src kinase activity and can be further activated by EGF. In contrast, STAT5a or STAT5b activation is dependent on EGFR kinase activity. However, the c-Src kinase modulates STAT5 activation in at least two ways: (1) by direct phosphorylation of STAT5b (at Tyr699); and (2) by phosphorylating the EGFR at Tyr845.
STATs as therapeutic targets
As shown in the model of Figure 2 , the overexpression of c-Src and its interaction with the EGFR provides a network of signaling that, through the STAT proteins, leads to the increased proliferation characteristic of tumorigenesis. Overexpression of c-Src leads to the constitutive activation of STAT3, increased DNA binding of STAT3 at DNA consensus elements, and the subsequent upregulation of genes involved in the cell cycle; thus resulting in increased proliferation. To this context is added overexpression of the EGF receptor. Activation of the EGFR by circulating growth factors (such as TGFa or EGF) leads to activation of the STAT5a and STAT5b proteins. STAT5 activation is further increased not only by the associated c-Src tyrosine kinase activity, but also by c-Src-mediated phosphorylation of tyrosine 845 of the EGFR. Thus, phosphorylation of Tyr845, a signal unique to c-Src and EGFR co-overexpressing cells, provides an additional signal to the proliferative pathway through the STAT pathway. That is, in addition to STAT3 activation, both STAT5a and STAT5b are activated, further fueling the cell cycle and increased proliferation. We speculate that the relative importance of each of these STAT proteins, and their contribution to the progression of a breast tumor, will depend on the expression level of these signaling molecules in the cell from which the tumor originates, as well as the milieu of growth factors secreted from the surrounding stromal and hematopoietic (cytokine producing) cells. Nevertheless, the convergence of the signaling pathways originating at the membrane of the cell to the STAT proteins, provides a common target for therapeutic intervention, the STAT3, STAT5a, and STAT5b proteins.
The potentially important role of STAT proteins in a number of human cancers makes them prime candidates for therapeutic intervention (Bowman et al., 2000; Seidel et al., 2000) . In vitro models have shown that dominantnegative forms of STAT3 or STAT5 can inhibit cellular proliferation and transformation. Effective therapy, especially in later state tumors, will require the targeting of multiple signaling pathways. It is becoming increasingly evident that multifaceted and multitargeted therapies will be required to treat cancers such as breast cancer that rely on complicated crosstalk between a number of signaling pathways. We propose that developing therapeutic reagents to target the STATs could be used in conjunction with other already defined therapies such as chemotherapy or radiation, or EGFR kinase inhibitors. Future studies on STAT signaling will elucidate the effectiveness of STAT targets for multifaceted therapy for a number of cancers.
